< Back to previous page


New perspectives on biological HDL-targeted therapies

Journal Contribution - Journal Article

According to a modified high-density lipoprotein (HDL) hypothesis, improving HDL function will lead to a decrease of coronary events. The stringent requirement for proving or refuting this hypothesis is that the causal pathway between the therapeutic intervention and a clinically meaningful endpoint obligatory passes through HDL. Infusion therapy of reconstituted HDL particles and human apolipoprotein A-I gene transfer are biological HDL-targeted therapies that are distinguished by HDL specificity. In addition, recombinant lecithin:cholesterol acyltransferase therapy is developed since this enzyme might be rate-limiting in patients with coronary heart disease. The potential of biological HDL-targeted therapies is discussed from a clinical perspective.
Journal: Expert Opinion on Biological Therapy
ISSN: 1471-2598
Issue: 7
Volume: 17
Pages: 793 - 796
Publication year:2017